



PREFERRED SPECIALTY MANAGEMENT POLICY

- POLICY:** Gaucher Disease – Substrate Reduction Therapy Preferred Specialty Management Policy
- Cerdelga™ (eliglustat capsules – Genzyme)
 - Zavesca® (miglustat capsules – Actelion, generic)
 - Yargesa® (miglustat capsules – Edenbridge [generic only])

REVIEW DATE: 10/22/2025

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Cerdelga and miglustat capsules (Zavesca, Yargesa) are substrate reduction therapy agents indicated for long-term therapy of **Type 1 Gaucher disease** in patients with a confirmed diagnosis.¹⁻³ Amongst the miglustat formulations, Yargesa is a branded generic product and is supplied in the same dosage strength as Zavesca. Cerdelga is specifically indicated for the long-term treatment of adult patients with Gaucher disease type 1 who are cytochrome P450 2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test.¹ Miglustat capsules are indicated as monotherapy for the treatment of adult patients with mild to moderate Gaucher disease type 1 for whom

enzyme replacement therapy is not a therapeutic option (e.g., due to allergy, hypersensitivity, or poor venous access).²

POLICY STATEMENT

This Preferred Specialty Management program has been developed to encourage the use of Preferred Products. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Prior Authorization Policy* criteria. The program also directs the patient to try the Preferred Product(s) prior to the approval of the Non-Preferred Product. Requests for the Non-Preferred Product will also be reviewed using the exception criteria (below). Patients meeting the Prior Authorization criteria for a Non-Preferred Product who have not tried the Preferred Product(s) will be offered a review for the Preferred Product. All approvals are provided for the duration noted below.

Documentation: Documentation is required for use of Cerdelga, Yargesa, and generic miglustat as noted in the criteria as **[documentation required]**. Documentation may include, but is not limited to chart notes, prescription claims records, and prescription receipts. All documentation must include patient-specific identifying information.

Preferred Product: Cerdelga, generic miglustat, Yargesa
Non-Preferred Product: Zavesca

Gaucher Disease – Substrate Reduction Therapy Preferred Specialty Management Policy non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.

NON-PREFERRED PRODUCT EXCEPTION CRITERIA

Non-Preferred Product	Exception Criteria
Zavesca	<p>1. <u>Gaucher Disease Type I.</u></p> <p>A) Approve for 1 year if the patient meets ALL of the following (i, ii, <u>and</u> iii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Gaucher Disease Substrate Reduction Therapy – Miglustat Prior Authorization</i> criteria; AND ii. Patient has tried Cerdelga (eliglustat capsules) [documentation required]; AND iii. Patient meets BOTH of the following (a <u>and</u> b): <ul style="list-style-type: none"> a) Patient has tried ONE of Yargesa or generic miglustat capsules [documentation required]; AND

	<p>b) Brand Zavesca is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product, which, per the prescriber has or would result in a significant allergy or serious adverse reaction.</p> <p>B) For a patient who meets criteria 1Ai but does not meet criteria 1Aii and 1Aiii, offer to review for one of the Preferred Products using the standard <i>Gaucher Disease Substrate Reduction Therapy – Cerdelga Prior Authorization</i> criteria or <i>Miglustat Prior Authorization</i> criteria.</p> <p>2. Other Conditions.</p> <p>A) Approve for 1 year if the patient meets BOTH of the following (i and ii):</p> <ul style="list-style-type: none"> i. Patient meets the standard <i>Gaucher Disease Substrate Reduction Therapy – Miglustat Prior Authorization</i> criteria; AND ii. Patient meets BOTH of the following (a and b): <ul style="list-style-type: none"> a) Patient has tried ONE of Yargesa or generic miglustat capsules [documentation required]; AND b) Brand Zavesca is being requested due to a formulation difference in the inactive ingredient(s) [e.g., preservatives] between the Brand and the bioequivalent generic product, which, per the prescriber has or would result in a significant allergy or serious adverse reaction. <p>B) For a patient who meets criteria 2Ai but does not meet criteria 2Aii, offer to review for one of Yargesa or generic miglustat capsules using the standard <i>Gaucher Disease Substrate Reduction Therapy – Miglustat Prior Authorization</i> criteria.</p>
--	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

REFERENCES

1. Cerdelga™ capsules [prescribing information]. Waterford, Ireland: Genzyme; January 2024.
2. Zavesca® capsules [prescribing information]. South San Francisco, CA: Actelion; August 2022.
3. Yargesa® capsules [prescribing information]. Parsippany, NJ: Edenbridge; July 2024.

HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	09/06/2023
Selected Revision	Added Yargesa, a branded generic miglustat product, to the Policy as a Preferred Product. Removed criteria regarding other conditions for approval.	12/06/2023
Annual Revision	No criteria changes.	10/02/2024
Selected Revision	Added criteria for approval of brand Zavesca for other conditions with supportive evidence.	11/20/2024
Annual Revision	No criteria changes.	10/22/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.